doi: 10.1016/j.cmet.2021.12.010 Summary Keywords GIP, GLP-1, obesity, weight loss, tirzepatide, GLP-1R agonists, GIP receptor agonists, Citation Zaffina I, Pelle MC, Armentaro G, Giofr F, Cassano V, Sciacqua A and Arturi F (2023) Effect of dual glucose-dependent insulinotropic peptide/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity
5 , 8163, doi: 10.1038/srep08163 (2015)
Furthermore, a meta-analysis suggested a possible association between GLP-1RAs therapy and an increased relative risk of thyroid cancer in clinical trials, with liraglutide, exenatide, and dulaglutide potentially elevating cancer risk in patients with type 2 diabetes [9]
Common side effects may include nausea, constipation, or GI upset, which is why ongoing medical supervision is essential
Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis
Intravenous Curcumin is frequently started at a low dose to assess tolerability
